|Nabilone,Dronabinol||cud in humans via placebo trial (n=14)||Subjective, cognitive, and cardiovascular dose-effect profile of nabilone and dronabinol in marijuana smokers||Jan 2012|
Ingestion Method: nabilone (2, 4, 6, 8 mg), dronabinol (10, 20 mg)|
Nabilone (4, 6, 8 mg) and dronabinol (10, 20 mg) increased ratings of feeling a good effect, a strong effect, and/or `high' relative to placebo; nabilone had a slower onset of peak subjective effects than dronabinol. Nabilone (6, 8 mg) modestly lowered psychomotor speed relative to placebo and dronabinol.
|Nabilone||fibromyalgia in humans via placebo trial (n=40)||Nabilone for the treatment of pain in fibromyalgia.||Feb 2008|
|Positive There were significant decreases in the VAS (-2.04, P < .02), FIQ (-12.07, P < .02), and anxiety (-1.67, P < .02) in the nabilone treated group at 4 weeks. There were no significant improvements in the placebo group. The treatment group experienced more side effects per person at 2 and 4 weeks (1.58, P < .02 and 1.54, P < .05), respectively. Nabilone appears to be a beneficial, well-tolerated treatment option for fibromyalgia patients, with significant benefits in pain relief and functional improvement.|
|Nabilone||sedative in humans via trial (n=29/31)||The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial.||Feb 2010|
Ingestion Method: 0.5-1.0 mg before bedtime|
Positive Nabilone is effective in improving sleep in patients with FM and is well tolerated. Low-dose nabilone given once daily at bedtime may be considered as an alternative to amitriptyline. Longer trials are needed to determine the duration of effect and to characterize long-term safety.
|Nabilone||pain via review||Nabilone for the Management of Pain.||Mar 2016|
|Eight randomized controlled trials, two prospective cohort trials, and one retrospective chart review were retrieved. Cancer pain, chronic noncancer pain, neuropathic pain, fibromyalgia, and pain associated with spasticity were the pain conditions evaluated. Nabilone was most commonly used as adjunctive therapy and led to small but significant reductions in pain.|
|Nabilone||chemotherapy,nausea in humans via trial (n=34)||Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy.||Nov 1983|
|Fewer subjects vomited with nabilone (P = 0.05) and the number of vomiting episodes was lower (P less than 0.05); no patients on nabilone required additional parenteral anti-emetic. More patients preferred nabilone for anti-emetic control (P less than 0.005).|
|Nabilone||chemotherapy,nausea in humans via trial (n=30)||Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: a double-blind, crossover trial.||Jun 1987|
|Positive On completion of the trial, 66% of the children stated that they preferred nabilone, 17% preferred prochlorperazine, and 17% had no preference (P = .015, chi 2 test).|
|Nabilone||chemotherapy,nausea||A double-blind, controlled trial of nabilone vs. prochlorperazine for refractory emesis induced by cancer chemotherapy.||Dec 1982|
|Nabilone||chemotherapy,nausea in humans via trial (n=24)||A cross-over comparison of nabilone and prochlorperazine for emesis induced by cancer chemotherapy.||Aug 1985|
|Nabilone was significantly superior to prochlorperazine in the reduction of vomiting episodes. Side effects, mainly vertigo, were evident in nearly half of the patients after nabilone, and three patients were withdrawn from the study due to decreased coordination and hallucinations after nabilone.|
|Nabilone||appetite boost,lung cancer in humans via placebo trial (n=65)||The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial.||Sep 2018|
Ingestion Method: 0.5 mg/2 weeks followed by 1.0 mg/6 weeks|
Positive Nabilone increased their caloric intake (342-kcal) and had a significantly higher intake of carbohydrates (64 g) compared to patients receiving placebo (p = 0.040). Quality of life also showed significant improvements in patients in the experimental arm of the trial, particularly in role functioning (p = 0.030), emotional functioning (p = 0.018), social functioning (p = 0.036), pain (p = 0.06), and insomnia (p = 0.020).